Augusta University
Chandramohan "Mohan" Wakade, MBBS
Associate Dean and Professor in College of Allied Health Sciences
- Augusta GA UNITED STATES
Chandramohan Wakade's research focus include trauma to the nervous system and neural repair.
Contact More Open optionsMultimedia
Areas of Expertise
Education
University of Poona
MBBS
Medicine
1986Fergusson College
BHS
Biology, General
1979Links
Media Appearances
Watch: Celebrate our Augusta University sweethearts for Valentine’s Day
Augusta University News online
2022-02-10
Dr. Mohan Wakade, associate dean of research, and Swati Wakade, a medical laboratory technician, both work at the College of Allied Health Sciences. They love science, lunch dates and Olive Garden.
Articles
Targeting a Granulocytic/Microbiome Axis Reverses Glioblastoma Progression via Intranasal Cannabidiol
bioRxiv2026-07-01
Mucosal cannabidiol formulations are known regulators of the glioblastoma microenvironment, yet the underlying origin point triggering this stroma-remodeling efficacy remains entirely unknown. Here, by mapping innate cell trafficking pathways, we define a novel baseline neuro-immune-microbiome axis in orthotopic glioblastoma, characterized by diverse microbial communities, likely seeded via blood-brain barrier disruption, paired with dense infiltration of host mast cells and mature, crystalloid-containing eosinophils.
Emerging urinary alpha-synuclein and miRNA biomarkers in Parkinson’s disease
Metabolic Brain Disease2022-08-01
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases after Alzheimer’s disease (AD), afflicting adults above the age of sixty irrespective of gender, race, ethnicity, and social status. PD is characterized by motor dysfunctions, displaying resting tremor, rigidity, bradykinesia, and postural imbalance. Non-motor symptoms, including rapid eye movement (REM) behavior disorder, constipation, and loss of sense of smell, typically occur many years before the appearance of the PD motor symptoms that lead to a diagnosis.
Low-dose niacin supplementation improves motor function in US Veterans with Parkinson’s disease: a single-center, randomized, placebo-controlled trial
Biomedicines2021-12-01
A six-month double-blind, placebo-controlled randomized study was conducted to ascertain whether low-dose daily niacin supplementation would improve motor symptoms in Parkinson’s disease (PD) patients. A total of 47 PD patients were assigned to receive low-dose niacin or a placebo. At the end of the double-blind phase, all participants received open-label niacin for the next six months. All patients were evaluated at baseline, after six months, and after one year of treatment. The primary outcome measure was the Unified Parkinson’s Disease Rating Scale III (UPDRS III) scores.
Niacin Enhancement for Parkinson’s Disease: An Effectiveness Trial
Frontiers in Aging Neuroscience2021-06-17
We previously reported that individuals with Parkinson’s disease (PD) present with lower vitamin B3 levels compared to controls. It may be related to carbidopa interaction, defective tryptophan metabolism, and stresses of night sleep disorder. Vitamin B3 is the energy source for all cells by producing NAD+ and NADP+ in redox reactions of oxidative phosphorylation. Thus, some symptoms of PD such as fatigue, sleep dysfunction, and mood changes may be related to the deficiency of vitamin B3. Here, we conducted an effectiveness trial to determine the effect of 12 months of low-dose niacin (a vitamin B3 derivative) enhancement in PD individuals. An average of 9 ± 6-point improvement in the Unified Parkinson’s Disease Rating Scale (UPDRS) III (motor) score was observed after 12 months of daily niacin compared to the expected decline in score (effect size = 0.78, 95% CI = 7–11).
Serum Levels of Inflammatory Proteins Are Associated With Peripheral Neuropathy in a Cross-Sectional Type-1 Diabetes Cohort
Frontiers in immunology2021-03-31
Chronic low-grade inflammation is involved in the pathogenesis of type-1 diabetes (T1D) and its complications. In this cross-section study design, we investigated association between serum levels of soluble cytokine receptors with presence of peripheral neuropathy in 694 type-1 diabetes patients. Sex, age, blood pressure, smoking, alcohol intake, HbA1c and lipid profile, presence of DPN (peripheral and autonomic), retinopathy and nephropathy was obtained from patient’s chart. Measurement of soluble cytokine receptors, markers of systemic and vascular inflammation was done using multiplex immunoassays. Serum levels were elevated in in DPN patients, independent of gender, age and duration of diabetes.
